Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Vaccines, Free Full-Text

PDF) Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular Therapy

Peptides for Vaccine Development

Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study - The Lancet Healthy Longevity

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study - The Lancet Oncology

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Frontiers Will Host Genetics Affect the Response to SARS-CoV-2 Vaccines? Historical Precedents

Frontiers Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis: Trends in Molecular Medicine

Covid vaccine efficacy and blood cancer

Frontiers Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide Study